COL6A3 Positive
1 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| T-Cell Infusion, Aldesleukin, and Utomilumab in Treating Patients With Recurrent Ovarian Cancer (NCT03318900) | M.D. Anderson Cancer Center | 2018-09-04 |
Track COL6A3 Positive automatically
Every clearance here is in the API, with alerts when new ones post.